title: Infliximab and primary Sjogren's syndrome: comment on the article by Mariette et al.
authors.forename: Izzet
authors.initials: I
authors.lastname: Fresko
authors.forename: Emire
authors.initials: E
authors.lastname: Seyahi
authors.forename: Sebahattin
authors.initials: S
authors.lastname: Yurdakul
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005356:Fibromyalgia / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D000069285:Infliximab; D016032:Randomized Controlled Trials as Topic; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D017211:Treatment Failure
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab